

**Top Enrolling Physicians for September 2012**

Physician	Patient Registrations	Treatment Credits	Control Credits	Total Credits
Dr. Braun	2	0	0	0
Dr. Biggers	2	0	2	2
Dr. Bonebrake	2	2	0.5	2.5
Dr. Carlson	2	0	2	2
Dr. Ellis	1	1	0	1
Dr. Graham	1	0	0	0
Dr. Gillett	1	1	0	1
Dr. Pinheiro	1	0	0	0
Dr. Tiriveedhi	2	2	0	2
<b>TOTALS</b>	<b>14</b>	<b>6</b>	<b>4.5</b>	<b>10.5</b>

We had 15 enrollments in September. Four were non-credit studies where we receive money instead of credits. Thus far this grant year, we have earned 32.4 treatment credits and need to be at 36.7 to meet our NCI target for the year – only 4.3 credits behind. We have earned 23.1 control credits and need to have 26.7 to meet NCI’s target for us – 3.6 behind.

**Study Profile**

Wake Forest 99311”Randomized Placebo-Controlled Phase 2 Pilot Study of Memantine (Namenda) for Smoking Cessation among Cancer Survivors” is our study to profile this month. This is a randomized, placebo controlled, pilot study assessing the feasibility of smoking cessation intervention in cancer survivors. Survivors of non-metastatic breast, prostate, colorectal cancers or Stage I/II non-small cell lung cancer are being recruited for the study. Eligibility requirements include: Six months past treatment, smoked 100 cigarettes over lifetime and who, at the time of the first interview, smoked 10 or more cigarettes per day on most days over the past month, willingness to adhere to the study protocol and attend required clinic visits, and willingness to stop Nicotine Replacement Therapy (or not start it) for duration of study.

**Congratulations Drs. Carlson, Bonebrake and Tiriveedhi**

At the CCOP/MBCOP Principal Investigators and Administrators meeting at NCI in Bethesda, MD on September 23 & 24, Dr. Jay Carlson and his staff were recognized for achieving the highest enrollment of patients on NCI cancer treatment clinical trials and treatment plus cancer control clinical trials for all CCOP/MBCOP programs. Drs. Al Bonebrake and Lavanya Tiriveedhi were recognized for exceptional achievement in NCI patient enrollments. Congratulations to all! We appreciate your continuing support.

**CRO Steering Committee Meeting**

Monday, October 15, 2012 is the date for our fall CRO Steering Committee meeting. Steven Sorcher MD from Washington University in St. Louis will be speaking on metastatic renal cell cancer. The title of his presentation is “Shedding Light on Second-line mRCC”. The meeting will be at TOUCH Restaurant beginning at 6PM. Pfizer is helping sponsor the program. Please contact CRO at 269-4520 to let us know you are coming by Thursday, October 11, 2012.

**Local Research Conference - “Community Based Research: The Time is Now”**

CoxHealth and Mercy have joined together to offer an educational and motivational conference. The conference will be held October 12-13, at McAuley Conference Center inside Mercy Hospital. The event will feature a variety of topics, and speakers and a lot of networking. Dr. Jim Atkins, who spoke at our very first CRO Steering committee years ago, is the key note speaker. The website to register is <http://www.coxhealth.com/body.cfm?id=5342>

**CRO Monthly Educational Conferences Cease**

The CRO Executive Committee discussed declining attendance at the CRO monthly educational WebEx conference held May through August 2012. It was decided to suspend these meetings at this time. CRO will obtain physician interest in studies by resuming our previous system of sending physicians written information regarding new trials and requesting their input.

## **New Studies Approved in September 2012**

### **Opened at Cox and Mercy Springfield**

**RTOG 1122** Phase II Double-Blinded Placebo-Controlled Study Of Bevacizumab with or without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma

**WF 99311** Randomized Placebo-Controlled Phase 2 Pilot Study of Memantine (Namenda) for Smoking Cessation among Cancer Survivors - Credentialing & training will need to be completed at each site prior to registering a patient.

### **Open at Mercy only**

**RTOG 0938** A Randomized Phase II Trial of Hypofractionated Radiotherapy For Favorable Risk Prostate Cancer

## **Studies Permanently Closed to Enrollment at Cox & Mercy in September 2012**

**GOG-0186G** A Phase II Randomized, Double Blinded Evaluation of Oral Everolimus (RAD001) Plus Bevacizumab vs. Oral Placebo Plus Bevacizumab in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

**SWOG S0518** Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC #704865) In Advanced, Poor Prognosis Carcinoid Patients

**NCCTG N09C6** Randomized Double-Blind Study of Doxepin Rinse versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy with or without Chemotherapy